Table 1.
Univariate and multivariate Cox regression analysis of PFS in ibrutinib-treated CLL
AnalysisHR (95% CI)P
Univariate analysis   
 Age ≥65 yr 0.48 (0.22–1.05) 0.068 
 Sex, male 0.50 (0.24–1.06) 0.071 
 III–IV Rai stage 1.30 (0.56–3.03) 0.548 
 Therapy, RR status 3.14 (1.09–9.01) 0.034 
 WBC count 1.00 (1.00–1.00) 0.364 
 β2M ≥4 mg/L 1.06 (0.43–2.62) 0.894 
 CD49d+ 3.32 (1.35–8.17) 0.009 
 UM IGHV 5.48 (1.65–18.17) 0.006 
 TP53 disrupted 2.71 (1.14–6.43) 0.025 
 Del11q 0.52 (0.16–1.74) 0.291 
Multivariate analysis   
 Model 1   
 CD49d+ 3.15 (1.16–8.53) 0.025 
 UM IGHV 4.17 (1.23–14.15) 0.023 
 TP53 disrupted 2.83 (1.18–6.82) 0.021 
 Model 2   
 CD49d+ 2.61 (1.03–6.61) 0.043 
 UM IGHV 4.32 (1.26–14.81) 0.020 
 Therapy, RR status 1.53 (0.50–4.65) 0.457 
 Model 3   
 CD49d+ 2.61 (0.95–7.16) 0.065 
 TP53 disrupted 3.00 (1.24–7.29) 0.016 
 Therapy, RR status 3.71 (0.83–16.59) 0.087 
AnalysisHR (95% CI)P
Univariate analysis   
 Age ≥65 yr 0.48 (0.22–1.05) 0.068 
 Sex, male 0.50 (0.24–1.06) 0.071 
 III–IV Rai stage 1.30 (0.56–3.03) 0.548 
 Therapy, RR status 3.14 (1.09–9.01) 0.034 
 WBC count 1.00 (1.00–1.00) 0.364 
 β2M ≥4 mg/L 1.06 (0.43–2.62) 0.894 
 CD49d+ 3.32 (1.35–8.17) 0.009 
 UM IGHV 5.48 (1.65–18.17) 0.006 
 TP53 disrupted 2.71 (1.14–6.43) 0.025 
 Del11q 0.52 (0.16–1.74) 0.291 
Multivariate analysis   
 Model 1   
 CD49d+ 3.15 (1.16–8.53) 0.025 
 UM IGHV 4.17 (1.23–14.15) 0.023 
 TP53 disrupted 2.83 (1.18–6.82) 0.021 
 Model 2   
 CD49d+ 2.61 (1.03–6.61) 0.043 
 UM IGHV 4.32 (1.26–14.81) 0.020 
 Therapy, RR status 1.53 (0.50–4.65) 0.457 
 Model 3   
 CD49d+ 2.61 (0.95–7.16) 0.065 
 TP53 disrupted 3.00 (1.24–7.29) 0.016 
 Therapy, RR status 3.71 (0.83–16.59) 0.087 

White blood cell count was considered as continuous variable. β2M, β2 microglobulin; CI, confidence interval; Del11q, according to Döhner et al. (2000); HR, hazard ratio; RR, relapsed-refractory; UM, unmutated; WBC, white blood cell.

or Create an Account

Close Modal
Close Modal